A Study of Cemiplimab With Chemotherapy and Immunotherapy in People With Head and Neck Cancer
Recruiting · Phase 1 · NCT04722523
Conditions: Head and Neck Cancer, Head Cancer, Head Cancer Neck, Neck Cancer, Head and Neck Squamous Cell Carcinoma, HNSCC
At a glance
- Research payments reported, 2025
- $284,148
- U.S. investigators named
- 1
- Sites paid
- 1
- Planned or actual enrollment
- 40
About the trial
- Sponsor
- Memorial Sloan Kettering Cancer Center (with Regeneron Pharmaceuticals)
- Tested
- Cisplatin (drug), Carboplatin (drug), Docetaxel (drug), Cetuximab (drug), Cemiplimab (drug), Surgical Resection of Primary +/- Neck Dissection (procedure), Post-operative radiation therapy (radiation), Paclitaxel (drug)
- Dates
- Started 2021-01-20; completion 2027-06-20
- Results posted
- Not yet
The purpose of this study is to find out whether combining the standard chemotherapy for head and neck cancer with the immunotherapy drugs cetuximab and cemiplimab (the study drug) is a safe treatment for head and neck cancer, and whether receiving this combination treatment before surgery may allow participants to forgo the standard radiation treatment after surgery.
From ClinicalTrials.gov, last updated 2026-07-21. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Regeneron Pharmaceuticals, Inc. reported $284,148 in research payments for this study in 2025 (3 payments).
Products named: Libtayo
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Memorial Sloan-Kettering Cancer Center $284,148
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.